Ascletis Says PD-L1/Chidamide Combination May Offer Cure for HIV

Hangzhou Ascletis reported that a combination of its PD-L1 inhibitor (ASC22) and Chidamide, a histone deacetylase inhibitor, was effective against HIV infection in an investigator-led Phase II trial. The trial evaluated the efficacy of the combination on viral reservoirs of latently infected cells in HIV-infected people. Although HIV is effectively treated using antiretroviral therapy (ART), patients are not cured and must continue ART. Almost all HIV-infected individuals will experience viral rebound if ART is discontinued. Ascletis said the combination therapy activated latent HIV reservoirs, with the possibility of offering a cure. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues: